Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologyDiseaseThyroid CancerSubgroupanaplasticBRAF V600E mutationICD10C73MeSHThyroid NeoplasmsSequenceVEMU(960/720)/COBI60, SD, C1 (PID2751) -|- ATEZ840/VEMU720/COBI60, C2+ (PID2750)ChemotherapyChemo-substanceAtezolizumabCobimetinibVemurafenibChemo-substanceAtezolizumabCobimetinibVemurafenibChemo-substanceAtezolizumabCobimetinibVemurafenibChemo-substanceAtezolizumabCobimetinibVemurafenibNo. Substances23 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionNo. Substances1Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HyperglycemiaHypertensionHyponatremiaIncrease AminotransferasesProteinuriaRash only studiesPublicationAuthorCabanillas MEDiseaseAnaplastiches Schilddrüsenkarzinom, lokal fortgeschritten, nicht operabel oder metastasiert, BRAF+, ECOG 0-2OriginDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, HoustonProtocols in Revision 2 protocols foundProtocols under revision.Atezolizumab 840 / Vemurafenib 720 / Cobimetinib 60, Thyroid Cancer, Cycle 2+ (PID2750 V1.0)Vemurafenib (960/720) / Cobimetinib 60, Thyroid Cancer, Cycle 1 (PID2751 V1.0)
